GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » ROA %

Kyorin Pharmaceutical Co (TSE:4569) ROA % : 4.86% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Kyorin Pharmaceutical Co's annualized Net Income for the quarter that ended in Dec. 2023 was 円8,628 Mil. Kyorin Pharmaceutical Co's average Total Assets over the quarter that ended in Dec. 2023 was 円177,559 Mil. Therefore, Kyorin Pharmaceutical Co's annualized ROA % for the quarter that ended in Dec. 2023 was 4.86%.

The historical rank and industry rank for Kyorin Pharmaceutical Co's ROA % or its related term are showing as below:

TSE:4569' s ROA % Range Over the Past 10 Years
Min: 2.32   Med: 3.67   Max: 7.41
Current: 2.43

During the past 13 years, Kyorin Pharmaceutical Co's highest ROA % was 7.41%. The lowest was 2.32%. And the median was 3.67%.

TSE:4569's ROA % is ranked better than
53.52% of 1080 companies
in the Drug Manufacturers industry
Industry Median: 1.705 vs TSE:4569: 2.43

Kyorin Pharmaceutical Co ROA % Historical Data

The historical data trend for Kyorin Pharmaceutical Co's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co ROA % Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.57 3.62 2.32 2.71 3.01

Kyorin Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 1.55 2.48 4.86 3.16

Competitive Comparison of Kyorin Pharmaceutical Co's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's ROA % distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's ROA % falls into.



Kyorin Pharmaceutical Co ROA % Calculation

Kyorin Pharmaceutical Co's annualized ROA % for the fiscal year that ended in Mar. 2024 is calculated as:

ROA %=Net Income (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=5322/( (176045+177679)/ 2 )
=5322/176862
=3.01 %

Kyorin Pharmaceutical Co's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=8628/( (176175+178942)/ 2 )
=8628/177558.5
=4.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Kyorin Pharmaceutical Co  (TSE:4569) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=8628/177558.5
=(Net Income / Revenue)*(Revenue / Total Assets)
=(8628 / 129320)*(129320 / 177558.5)
=Net Margin %*Asset Turnover
=6.67 %*0.7283
=4.86 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Kyorin Pharmaceutical Co ROA % Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines